Home › Major Depressive Disorder › Washington › Seattle
Major Depressive Disorder clinical trials in Seattle, WA
6 studies for Major Depressive Disorder are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RecruitingPhase 3
- Seattle Neuropsychiatric Treatment Center, Seattle
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
RecruitingPhase 2
- Draig Clinical Site, Seattle
Positive Processes and Transition to Health (PATH)
Recruiting
- University of Washington, Seattle
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
RecruitingPhase 3
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
RecruitingPhase 3
- Seattle Neuropsychiatric Treatment Center, Seattle
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
Recruiting
- University of Washington Medical Center, Seattle
Major Depressive Disorder trials in other cities
- New York City, NY37 studies
- Boston, MA31 studies
- Atlanta, GA25 studies
- Philadelphia, PA23 studies
- Orlando, FL19 studies
- Miami, FL18 studies
- Tampa, FL17 studies
- Chicago, IL17 studies
- Houston, TX16 studies
- San Diego, CA16 studies
- Little Rock, AR14 studies
- Las Vegas, NV13 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.